US7977493B2 - Chemiluminescent reagents - Google Patents

Chemiluminescent reagents Download PDF

Info

Publication number
US7977493B2
US7977493B2 US11/494,991 US49499106A US7977493B2 US 7977493 B2 US7977493 B2 US 7977493B2 US 49499106 A US49499106 A US 49499106A US 7977493 B2 US7977493 B2 US 7977493B2
Authority
US
United States
Prior art keywords
solution
chemiluminescent
chemiluminescent reagent
mmol
test tube
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related, expires
Application number
US11/494,991
Other versions
US20080027222A1 (en
Inventor
Osamu Nozaki
Motonori Munesue
Hiroko Kawamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemco Scientific Co Ltd
Kawamoto Hiroko
Munesue Motonori
Original Assignee
Chemco Scientific Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemco Scientific Co Ltd filed Critical Chemco Scientific Co Ltd
Priority to US11/494,991 priority Critical patent/US7977493B2/en
Assigned to CHEMCO SCIENTIFIC CO., LTD. reassignment CHEMCO SCIENTIFIC CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KAWAMOTO, HIROKO, MUNESUE, MOTONORI, NOZAKI, OSAMU
Assigned to KAWAMOTO, HIROKO, NOZAKI, OSAMU, CHEMCO SCIENTIFIC CO., LTD., MUNESUE, MOTONORI reassignment KAWAMOTO, HIROKO ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHEMCO SCIENTIFIC CO., LTD.
Publication of US20080027222A1 publication Critical patent/US20080027222A1/en
Application granted granted Critical
Publication of US7977493B2 publication Critical patent/US7977493B2/en
Expired - Fee Related legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • C07D473/34Nitrogen atom attached in position 6, e.g. adenine

Definitions

  • the present invention relates to novel chemiluminescent reagents for use in the detection and quantification of various substances, for example, in clinical applications.
  • chemiluminescence measurements are suitable for clinical tests in terms of their simple availability, promptness and high sensitivity.
  • Enzymes used for the chemiluminescence measurements are peroxidases, alkaline phosphotases, glycol oxidases, and the like.
  • Suitable chemiluminescent substances used for the chemiluminescence measurements are luminol, isoluminol, lophine, lucigenin, peryoxalate, and the like. See, the following Patent Publication Nos. 1 to 6.
  • chemiluminescent substances have the disadvantages of relatively poor solubility in water, which is essential for chemiluminescent detection, incorporation of impurities, and possible degradation during storage.
  • luminol and peryoxalate are required to be dissolved in organic solvents, such as acetonitrile, for the preparation of high-concentration solutions.
  • Lucigenin has the problems of short luminescence retention and severe background noise.
  • Lophine chemiluminescence has the problems of poor water solubility and low luminescence yield.
  • the present invention has been made in view of the above problems of the conventional chemiluminescent substances used for chemiluminescence measurements, and it is an object of the present invention to provide novel chemiluminescent substances that have a sensitivity comparable to that of luminol chemiluminescence, are highly water-soluble, have no incorporation of impurities, are not degraded during storage, have high reproducibility in measurement results, and are very suitable for use in the detection and quantification of various substances in many applications, e.g., clinical applications.
  • a chemiluminescent reagent which is prepared by freezing a solution of a peroxidized nitrogen-containing five-membered cyclic compound.
  • a chemiluminescent reagent which is prepared by lyophilizing a solution of a peroxidized nitrogen-containing five-membered cyclic compound.
  • the nitrogen-containing five-membered cyclic compound is selected from pyrrole, imidazole, and purine compounds.
  • the chemiluminescent reagents of the present invention are prepared by freezing or lyophilizing a solution of a peroxidized nitrogen-containing five-membered cyclic compound. Specifically, the chemiluminescent reagents of the present invention are prepared by reacting a solution a nitrogen-containing five-membered cyclic compound, an aqueous hydrogen peroxide solution and an alkaline buffer, and freezing or lyophilizing the reaction solution.
  • the chemiluminescent reagents of the present invention are prepared by introducing a solution of a nitrogen-containing five-membered cyclic compound, an aqueous hydrogen peroxide solution and an alkaline buffer into a test tube, reacting the mixture under heating to about 40° C. to about 60° C. for about 30 minutes, and directly freezing or lyophilizing the test tube.
  • Storage stability of the chemiluminescent reagents of the present invention could be achieved by simply freezing or lyophilization of the reaction solution or a fraction obtained by high-performance liquid chromatography of the reaction solution.
  • the frozen chemiluminescent reagent of the present invention is allowed to thaw at room temperature and is then used for the detection and quantification of various substances.
  • the lyophilized chemiluminescent reagent of the present invention is dissolved in distilled water in the same volume removed by the lyophilization, and is then used for the detection and quantification of various substances.
  • the nitrogen-containing five-membered cyclic compound used to prepare the chemiluminescent reagents according to the present invention is selected from pyrrole, imidazole, and purine compounds.
  • suitable pyrrole compounds include, but are not limited to, pyrrole, proline, and porphyrin.
  • suitable imidazole compounds include, but are not limited to, imidazole, 2-methylimidazole, 4-methylimidazole, 4-methyl-5-hydroxymethylimidazole, benzimidazole, 4-nitroimidazole, alantoin, ethylene urea, histidine, and pyrazole.
  • purine compounds include, but are not limited to, theophylline, caffeine, xanthine, allopurinol, inosine, tryptophan, adenine, adenosine, nicotine amide adenine dinucleotide (NAD), reduced nicotine amide adenine dinucleotide (NADH), adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenosine monophosphate (AMP), cyclic AMP, serotonin, and aciclovir.
  • theophylline caffeine, xanthine, allopurinol, inosine, tryptophan
  • adenine, adenosine nicotine amide adenine dinucleotide (NAD), reduced nicotine amide adenine dinucleotide (NADH), adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenosine mono
  • Non-limiting examples of suitable alkaline buffers that can be used to prepare the chemiluminescent reagents of the present invention include Tricine buffers, Tris hydrochloride buffers, and borate buffers.
  • the concentration of the alkaline buffer used is dependent on the kind of the buffer.
  • a Tricine buffer (pH 9.4) having a concentration of 50 mmol/L is used in the present invention.
  • the aqueous hydrogen peroxide solution used to prepare the chemiluminescent reagents of the present invention preferably has a concentration of about 100 mmol/L.
  • the chemiluminescent reagent After the test tube containing the chemiluminescent reagent thus prepared was taken out of the freezer, the chemiluminescent reagent was thawed at room temperature to obtain a solution. 50 ⁇ l of the solution was injected into a flow cell filled with an immobilized peroxidase enzyme using a flow injection system. As a result, it could be confirmed that the chemiluminescent reagent showed a chemiluminescence intensity comparable to that of luminol chemiluminescence.
  • the chemiluminescent reagent After the test tube containing the chemiluminescent reagent thus prepared was taken out of the freezer, the chemiluminescent reagent was thawed at room temperature to obtain a solution. 50 ⁇ l of the solution was injected into a flow cell filled with an immobilized peroxidase enzyme using a flow injection system. As a result, it could be confirmed that the chemiluminescent reagent showed a chemiluminescence intensity comparable to that of luminol chemiluminescence.
  • the chemiluminescent reagent After the test tube containing the chemiluminescent reagent thus prepared was taken out of the freezer, the chemiluminescent reagent was thawed at room temperature to obtain a solution. 50 ⁇ l of the solution was injected into a flow all filled with an immobilized peroxidase enzyme using a flow injection system. As a result, it could be confirmed that the chemiluminescent reagent showed a chemiluminescence intensity comparable to that of luminol chemiluminescence.
  • each chemiluminescent reagent thus prepared was taken out of the freezer, the chemiluminescent reagent was thawed at room temperature to obtain a solution. 50 ⁇ l of the solution was injected into a flow cell filled with an immobilized peroxidase enzyme using a flow injection system. As a result, it could be confirmed that all the chemiluminescent reagents showed a chemiluminescence intensity comparable to that of luminol chemiluminescence.
  • the chemiluminescent reagent After the test tube containing the chemiluminescent reagent thus prepared was taken out of the freezer, the chemiluminescent reagent was thawed at room temperature to obtain a solution. 50 ⁇ l of the solution was injected into a flow cell filled with an immobilized peroxidase enzyme using a flow infection system. As a result, it could be confirmed that the chemiluminescent reagent showed a chemiluminescence intensity comparable to that of luminol chemiluminescence.
  • each chemiluminescent reagent thus prepared was taken out of the freezer, the chemiluminescent reagent was thawed at room temperature to obtain a solution. 50 ⁇ l of the solution was injected into a flow cell filled with an immobilized peroxidase enzyme using a flow injection system. As a result, it could be confirmed that all the chemiluminescent reagents showed a chemiluminescence intensity comparable to that of luminol chemiluminescence.
  • chemiluminescent reagent showed a chemiluminescence intensity comparable to that of luminol chemiluminescence.
  • chemiluminescent reagent showed a chemiluminescence intensity comparable to that of luminol chemiluminescence.
  • chemiluminescent reagent showed a chemiluminescence intensity comparable to that of luminol chemiluminescence.
  • chemiluminescent reagent showed a chemiluminescence intensity comparable to that of luminol chemiluminescence.
  • the chemiluminescent substances of the present invention have a sensitivity comparable to that of luminol chemiluminescence, are highly water soluble, have no incorporation of impurities, are not degraded during storage, emit light by direct oxidation, have high reproducibility in measurement results, and are very suitable for use in the detection and quantification of various substances in many applications, e.g., clinical applications.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Chemiluminescent substances are prepared by freezing or lyophilizing a solution of a peroxidized nitrogen-containing five-membered cyclic compound.
The chemiluminescent substances have a sensitivity comparable to that of luminol chemiluminescence, are highly water-soluble, have no incorporation of impurities, are not degraded during storage, have high reproducibility in measurement results, and are very suitable for use in the detection and quantification of various substances in many applications, e.g., clinical applications.

Description

BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to novel chemiluminescent reagents for use in the detection and quantification of various substances, for example, in clinical applications.
2. Description of the Related Art
Many clinical methods have been developed to label substances with enzymes and measure the activity of the labeled enzymes by chemiluminescence. Such chemiluminescence measurements are suitable for clinical tests in terms of their simple availability, promptness and high sensitivity. Enzymes used for the chemiluminescence measurements are peroxidases, alkaline phosphotases, glycol oxidases, and the like. Suitable chemiluminescent substances used for the chemiluminescence measurements are luminol, isoluminol, lophine, lucigenin, peryoxalate, and the like. See, the following Patent Publication Nos. 1 to 6.
  • (Patent Publication No. 1) Japanese Patent Application Laid-Open No. Sho 59-171839
  • (Patent Publication No. 2) Japanese Patent Application Laid-Open No. Hei 2-174694
  • (Patent Publication No. 3) Japanese Patent Application Laid-Open No. Hei 2-291299
  • (Patent Publication No. 4) Japanese Patent Application Laid-Open No. Hei 3-35147
  • (Patent Publication No. 5) Japanese Patent Application Laid-Open No. Hei 7-327694
  • (Patent Publication No. 6) Japanese Patent Application Laid-Open No. Hei 8-313443
However, these chemiluminescent substances have the disadvantages of relatively poor solubility in water, which is essential for chemiluminescent detection, incorporation of impurities, and possible degradation during storage.
Specifically, luminol and peryoxalate are required to be dissolved in organic solvents, such as acetonitrile, for the preparation of high-concentration solutions. Lucigenin has the problems of short luminescence retention and severe background noise. Lophine chemiluminescence has the problems of poor water solubility and low luminescence yield.
SUMMARY OF THE INVENTION
Therefore, the present invention has been made in view of the above problems of the conventional chemiluminescent substances used for chemiluminescence measurements, and it is an object of the present invention to provide novel chemiluminescent substances that have a sensitivity comparable to that of luminol chemiluminescence, are highly water-soluble, have no incorporation of impurities, are not degraded during storage, have high reproducibility in measurement results, and are very suitable for use in the detection and quantification of various substances in many applications, e.g., clinical applications.
In accordance with one aspect of the present invention, there is provided a chemiluminescent reagent which is prepared by freezing a solution of a peroxidized nitrogen-containing five-membered cyclic compound.
In accordance with another aspect of the present invention, there is provided a chemiluminescent reagent which is prepared by lyophilizing a solution of a peroxidized nitrogen-containing five-membered cyclic compound.
In preferred embodiments of the present invention, the nitrogen-containing five-membered cyclic compound is selected from pyrrole, imidazole, and purine compounds.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
The chemiluminescent reagents of the present invention will now be described in detail.
The chemiluminescent reagents of the present invention are prepared by freezing or lyophilizing a solution of a peroxidized nitrogen-containing five-membered cyclic compound. Specifically, the chemiluminescent reagents of the present invention are prepared by reacting a solution a nitrogen-containing five-membered cyclic compound, an aqueous hydrogen peroxide solution and an alkaline buffer, and freezing or lyophilizing the reaction solution.
More specifically, the chemiluminescent reagents of the present invention are prepared by introducing a solution of a nitrogen-containing five-membered cyclic compound, an aqueous hydrogen peroxide solution and an alkaline buffer into a test tube, reacting the mixture under heating to about 40° C. to about 60° C. for about 30 minutes, and directly freezing or lyophilizing the test tube.
Storage stability of the chemiluminescent reagents of the present invention could be achieved by simply freezing or lyophilization of the reaction solution or a fraction obtained by high-performance liquid chromatography of the reaction solution. The frozen chemiluminescent reagent of the present invention is allowed to thaw at room temperature and is then used for the detection and quantification of various substances. Alternatively, the lyophilized chemiluminescent reagent of the present invention is dissolved in distilled water in the same volume removed by the lyophilization, and is then used for the detection and quantification of various substances.
The nitrogen-containing five-membered cyclic compound used to prepare the chemiluminescent reagents according to the present invention is selected from pyrrole, imidazole, and purine compounds. Examples of suitable pyrrole compounds include, but are not limited to, pyrrole, proline, and porphyrin. Examples of suitable imidazole compounds include, but are not limited to, imidazole, 2-methylimidazole, 4-methylimidazole, 4-methyl-5-hydroxymethylimidazole, benzimidazole, 4-nitroimidazole, alantoin, ethylene urea, histidine, and pyrazole. Examples of suitable purine compounds include, but are not limited to, theophylline, caffeine, xanthine, allopurinol, inosine, tryptophan, adenine, adenosine, nicotine amide adenine dinucleotide (NAD), reduced nicotine amide adenine dinucleotide (NADH), adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenosine monophosphate (AMP), cyclic AMP, serotonin, and aciclovir.
Non-limiting examples of suitable alkaline buffers that can be used to prepare the chemiluminescent reagents of the present invention include Tricine buffers, Tris hydrochloride buffers, and borate buffers. The concentration of the alkaline buffer used is dependent on the kind of the buffer. A Tricine buffer (pH 9.4) having a concentration of 50 mmol/L is used in the present invention.
The aqueous hydrogen peroxide solution used to prepare the chemiluminescent reagents of the present invention preferably has a concentration of about 100 mmol/L.
EXAMPLES
In the following examples, various chemiluminescent reagents of the present invention were prepared and used to measure the activity of peroxidases.
Example 1
2 mL of a 0.1 mol/L pyrrole solution (pH adjustment with a 50 mmol/L Scene buffer) was introduced into a test tube, and then 0.2 mL of an aqueous hydrogen peroxide (100 mmol) solution was added thereto. The mixture was allowed to react at about 60° C. for about 30 minutes. Thereafter, the test tube was placed and frozen in a freezer, giving a chemiluminescent reagent of the present invention.
After the test tube containing the chemiluminescent reagent thus prepared was taken out of the freezer, the chemiluminescent reagent was thawed at room temperature to obtain a solution. 50 μl of the solution was injected into a flow cell filled with an immobilized peroxidase enzyme using a flow injection system. As a result, it could be confirmed that the chemiluminescent reagent showed a chemiluminescence intensity comparable to that of luminol chemiluminescence.
Example 2
2 mL of a 0.1 mol/L proline solution (pH adjustment with a 50 mmol/L Tricine buffer) was introduced into a test tube, and then 0.2 mL of an aqueous hydrogen peroxide (100 mmol) solution was added thereto. The mixture was allowed to react at about 60° C. for about 30 minutes. Thereafter, the test tube was placed and frozen in a freezer, giving a chemiluminescent reagent of the present invention.
After the test tube containing the chemiluminescent reagent thus prepared was taken out of the freezer, the chemiluminescent reagent was thawed at room temperature to obtain a solution. 50 μl of the solution was injected into a flow cell filled with an immobilized peroxidase enzyme using a flow injection system. As a result, it could be confirmed that the chemiluminescent reagent showed a chemiluminescence intensity comparable to that of luminol chemiluminescence.
Example 3
2 mL of a 0.1 mol/L imidazole solution (pH adjustment with a 50 mmol/L Tricine buffer) was introduced into a test tube, and then 0.2 mL of an aqueous hydrogen peroxide (100 mmol) solution was added thereto. The mixture was allowed to react at about 60° C. for about 30 minutes. Thereafter, the test tube was placed and frozen in a freezer, giving a chemiluminescent reagent of the present invention.
After the test tube containing the chemiluminescent reagent thus prepared was taken out of the freezer, the chemiluminescent reagent was thawed at room temperature to obtain a solution. 50 μl of the solution was injected into a flow all filled with an immobilized peroxidase enzyme using a flow injection system. As a result, it could be confirmed that the chemiluminescent reagent showed a chemiluminescence intensity comparable to that of luminol chemiluminescence.
Examples 4 to 12
2 mL of each of a 2-methylimidazole solution (Example 4), a 4-methylimidazole solution (Example 5), a 4-methyl-5-hydroxymethylimidazole solution (Example 6), a benzimidazole solution (Example 7), a 4-nitroimidazole solution (Example 8), an alantoin solution (Example 9), an ethylene urea solution (Example 10), a histidine solution (Example 11), and a pyrazole solution (Example 12) (all of which had a concentration of 0.1 mol/L and were pH-adjusted with a 50 mmol/L Tricine buffer) was introduced into a test tube, and then 0.2 mL of an aqueous hydrogen peroxide (100 mmol) solution was added thereto. Each mixture was allowed to react at about 60° C. for about 30 minutes. Thereafter, the test tubes were placed and frozen in a freezer, giving chemiluminescent reagents of the present invention.
After the test tube containing each chemiluminescent reagent thus prepared was taken out of the freezer, the chemiluminescent reagent was thawed at room temperature to obtain a solution. 50 μl of the solution was injected into a flow cell filled with an immobilized peroxidase enzyme using a flow injection system. As a result, it could be confirmed that all the chemiluminescent reagents showed a chemiluminescence intensity comparable to that of luminol chemiluminescence.
Example 13
2 mL of a 0.1 mol/L theophylline solution (pH adjustment with a 50 mmol/L Tricine buffer) was introduced into a test tube, and then 0.2 mL of an aqueous hydrogen peroxide (100 mmol) solution was added thereto. The mixture was allowed to react at about 60° C. for about 30 minutes. Thereafter, the test tube was placed and frozen in a freezer, giving a chemiluminescent reagent of the present invention.
After the test tube containing the chemiluminescent reagent thus prepared was taken out of the freezer, the chemiluminescent reagent was thawed at room temperature to obtain a solution. 50 μl of the solution was injected into a flow cell filled with an immobilized peroxidase enzyme using a flow infection system. As a result, it could be confirmed that the chemiluminescent reagent showed a chemiluminescence intensity comparable to that of luminol chemiluminescence.
Examples 14 to 26
2 mL of each of a caffeine solution (Example 14), a xanthine solution (Example 15), an allopurinol solution (Example 16), an inosine solution (Example 17), a tryptophan solution (Example 18), an adenine solution (Example 19), an adenosine solution (Example 20), an NAD solution (Example 21), an NADH solution (Example 22), an ATP solution (Example 23), an ADP solution (Example 24), an AMP solution (Example 25), and a cyclic AMP solution (Example 26) (all of which had a concentration of 0.1 mol/L and were pH-adjusted with a 50 mmol/L Tricine buffer) was introduced into a test tube, and then 0.2 mL of an aqueous hydrogen peroxide (100 mmol) solution was added thereto. Each mixture was allowed to react at about 60° C. for about 30 minutes. Thereafter, the test tubes were placed and frozen in a freezer, giving chemiluminescent reagents of the present invention.
After the test tube containing each chemiluminescent reagent thus prepared was taken out of the freezer, the chemiluminescent reagent was thawed at room temperature to obtain a solution. 50 μl of the solution was injected into a flow cell filled with an immobilized peroxidase enzyme using a flow injection system. As a result, it could be confirmed that all the chemiluminescent reagents showed a chemiluminescence intensity comparable to that of luminol chemiluminescence.
Example 27
2 mL of a 0.1 mol/L pyrrole solution (pH adjustment with a 50 mmol/L Tricine buffer) was introduced into a test tube, and then 0.2 mL of an aqueous hydrogen peroxide (100 mmol) solution was added thereto. The mixture was allowed to react at about 60° C. for about 30 minutes. Thereafter, the test tube was placed and lyophilized in a freeze-dryer, giving a chemiluminescent reagent of the present invention.
2 mL of distilled water was added to the test tube to dissolve the chemiluminescent reagent. 50 μl of the solution was injected into a flow cell filled with an immobilized peroxidase enzyme using a flow injection system. As a result, it could be confirmed that the chemiluminescent reagent showed a chemiluminescence intensity comparable to that of luminol chemiluminescence.
Example 28
2 mL of a 0.1 mol/L proline solution (pH adjustment with a 50 mmol/L Tricine buffer) was introduced into a test tube, and then 0.2 mL of an aqueous hydrogen peroxide (100 mmol) solution was added thereto. The mixture was allowed to react at about 60° C. for about 30 minutes. Thereafter, the test tube was placed and lyophilized in a breeze-dryer, giving a chemiluminescent reagent of the present invention.
2 mL of distilled water was added to the test tube to dissolve the chemiluminescent reagent. 50 μl of the solution was injected into a flow cell filled with an immobilized peroxidase enzyme using a flaw injection system. As a result, it could be confirmed that the chemiluminescent reagent showed a chemiluminescence intensity comparable to that of luminol chemiluminescence.
Example 29
2 mL of a 0.1 mol/L imidazole solution (pH adjustment with a 50 mmol/L Tricine buffer) was introduced into a test tube, and then 0.2 mL of an aqueous hydrogen peroxide (100 mol) solution was added thereto. The mixture was allowed to react at about 60° C. for about 30 minutes. Thereafter, the test tube was placed and lyophilized in a freeze-dryer, giving a chemiluminescent reagent of the present invention.
2 mL of distilled water was added to the test tube to dissolve the chemiluminescent reagent. 50 μl of the solution was injected into a flow cell filled with an immobilized peroxidase enzyme using a flow injection system. As a result, it could be confirmed that the chemiluminescent reagent showed a chemiluminescence intensity comparable to that of luminol chemiluminescence.
Examples 30 to 38
2 mL of each of a 2-methylimidazole solution (Example 30), a 4-methylimidazole solution (Example 31), a 4-methyl-5-hydroxymethylimidazole solution (Example 32), a benzimidazole solution (Example 33), a 4-nitroimidazole solution (Example 34), an alantoin solution (Example 35), an ethylene urea solution (Example 36), a histidine solution (Example 37), and a pyrazole solution (Example 38) (all of which had a concentration of 0.1 mol/L and were pH-adjusted with a 50 mmol/L Tricine buffer) was introduced into a test tube, and then 0.2 mL of an aqueous hydrogen peroxide (100 mmol) solution was added thereto. Each mixture was allowed to react at about 60° C. for about 30 minutes. Thereafter, the test tubes were placed and lyophilized in a freeze-dryer, giving chemiluminescent reagents of the present invention.
2 mL of distilled water was added to the test tube containing each chemiluminescent reagent thus prepared to dissolve the chemiluminescent reagent. 50 μl of the solution was injected into a flow cell filled with an immobilized peroxidase enzyme using a flow injection system. As a result, it could be confirmed that all the chemiluminescent reagents showed a chemiluminescence intensity comparable to that of luminol chemiluminescence.
Example 39
2 mL of a 0.1 mol/L theophylline solution (pH adjustment with a 50 mmol/L Tricine buffer) was introduced into a test tube, and then 0.2 mL of an aqueous hydrogen peroxide (100 mmol) solution was added thereto. The mixture was allowed to react at about 60° C. for about 30 minutes. Thereafter, the test tube was placed and lyophilized in a freeze-dryer, giving a chemiluminescent reagent of the present invention.
2 mL of distilled water was added to the test tube to dissolve the chemiluminescent reagent. 50 μl of the solution was injected into a flow cell filled with an immobilized peroxidase enzyme using a flow injection system. As a result, it could be confirmed that the chemiluminescent reagent showed a chemiluminescence intensity comparable to that of luminol chemiluminescence.
Examples 40 to 52
2 mL of each of a caffeine solution (Example 40), a xanthine solution (Example 41), an allopurinol solution (Example 42), an inosine solution (Example 43), a tryptophan solution (Example 44), an adenine solution (Example 45), an adenosine solution (Example 46), an NAD solution (Example 47), an NADH solution (Example 48), an ATP solution (Example 49), an ADP solution (Example 50), an AMP solution (Example 51), and a cyclic AMP solution (Example 52) (all of which had a concentration of 0.1 mol/L and were pH-adjusted with a 50 mmol/L Tricine buffer) was introduced into a test tube, and then 0.2 mL of an aqueous hydrogen peroxide (100 mmol) solution was added thereto. Each mixture was allowed to react at about 60° C. for about 30 minutes. Thereafter, the test tubes were placed and lyophilized in a freeze-dryer, giving chemiluminescent reagents of the present invention.
2 mL of distilled water was added to the test tube containing each chemiluminescent reagent thus prepared to dissolve the chemiluminescent reagent. 50 μl of the solution was injected into a flow cell filled with an immobilized peroxidase enzyme using a flow injection system. As a result, it could be confirmed that all the chemiluminescent reagents showed a chemiluminescence intensity comparable to that of luminol chemiluminescence.
As apparent from the above description, the chemiluminescent substances of the present invention have a sensitivity comparable to that of luminol chemiluminescence, are highly water soluble, have no incorporation of impurities, are not degraded during storage, emit light by direct oxidation, have high reproducibility in measurement results, and are very suitable for use in the detection and quantification of various substances in many applications, e.g., clinical applications.

Claims (6)

1. In a chemiluminescent reagent which detects a target substance by the emission of light, the improvement comprising the chemiluminescent reagent being prepared by freezing an aqueous solution consisting of a peroxidized imidazole chemiluminescence material and a tricine buffer, wherein the aqueous solution is produced by mixing an aqueous hydrogen peroxide solution, an imidazole solution and a tricine buffer.
2. The chemiluminescent reagent of claim 1, wherein the tricine buffer has a concentration of 50 mmol/L.
3. The chemiluminescent reagent of claim 1, wherein the aqueous hydrogen peroxide solution has a concentration of about 100 mmol/L and the imidazole solution has a concentration of 0.1 mol/L.
4. In a chemiluminescent reagent which detects a target substance by the emission of light, the improvement comprising the chemiluminescent reagent being prepared by lyophilizing an aqueous solution consisting of a peroxidized imidazole chemiluminescence material and a tricine buffer, wherein the aqueous solution is produced by mixing an aqueous hydrogen peroxide solution, an imidazole solution and a tricine buffer.
5. The chemiluminescent reagent of claim 4, wherein the tricine buffer has a concentration of 50 mmol/L.
6. The chemiluminescent reagent of claim 4, wherein the aqueous hydrogen peroxide solution has a concentration of about 100 mmol/L and the imidazole solution has a concentration of 0.1 mol/L.
US11/494,991 2006-07-28 2006-07-28 Chemiluminescent reagents Expired - Fee Related US7977493B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/494,991 US7977493B2 (en) 2006-07-28 2006-07-28 Chemiluminescent reagents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/494,991 US7977493B2 (en) 2006-07-28 2006-07-28 Chemiluminescent reagents

Publications (2)

Publication Number Publication Date
US20080027222A1 US20080027222A1 (en) 2008-01-31
US7977493B2 true US7977493B2 (en) 2011-07-12

Family

ID=38987190

Family Applications (1)

Application Number Title Priority Date Filing Date
US11/494,991 Expired - Fee Related US7977493B2 (en) 2006-07-28 2006-07-28 Chemiluminescent reagents

Country Status (1)

Country Link
US (1) US7977493B2 (en)

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59171839A (en) 1983-02-11 1984-09-28 ナシヤナル、リサ−チ、デイヴエラツプマント、コ−パレイシヤン Sensitized luminescence test method
US4598044A (en) 1983-02-11 1986-07-01 National Research Development Corporation Enhanced luminescent or luminometric assay
US4645646A (en) * 1983-07-29 1987-02-24 Henning Berlin Gmbh Chemie-Und Pharmawerk Luminescence immunoassay for haptens and chemiluminescence labelled hapten conjugates
US4835101A (en) * 1986-02-10 1989-05-30 Kallestad Diagnostics, Inc. Luminescent analyses with enhanced storage stability
JPH02174694A (en) 1988-09-30 1990-07-06 Fujirebio Inc Chemiluminescent assay for peroxidase activity
JPH02291299A (en) 1989-02-14 1990-12-03 Takeda Chem Ind Ltd Method for enhancing chemiluminescence
JPH0335147A (en) 1989-07-03 1991-02-15 Doujin Kagaku Kenkyusho:Kk Detection of chemiluminescence
US5106732A (en) 1989-02-14 1992-04-21 Takeda Chemical Industries, Ltd. Method for enhancement of chemiluminescence
JPH07327694A (en) 1994-06-14 1995-12-19 Hitachi Chem Co Ltd Reagent for chemoluminescence measurement and measuring method therefor
JPH08313443A (en) 1995-05-19 1996-11-29 Kdk Corp Modified chemiluminescence measuring method
US6565894B1 (en) * 1999-11-05 2003-05-20 Francis X. Smith Healthcare formulations comprising imidazole and hydrogen peroxide

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59171839A (en) 1983-02-11 1984-09-28 ナシヤナル、リサ−チ、デイヴエラツプマント、コ−パレイシヤン Sensitized luminescence test method
US4598044A (en) 1983-02-11 1986-07-01 National Research Development Corporation Enhanced luminescent or luminometric assay
US4645646A (en) * 1983-07-29 1987-02-24 Henning Berlin Gmbh Chemie-Und Pharmawerk Luminescence immunoassay for haptens and chemiluminescence labelled hapten conjugates
US4835101A (en) * 1986-02-10 1989-05-30 Kallestad Diagnostics, Inc. Luminescent analyses with enhanced storage stability
JPH02174694A (en) 1988-09-30 1990-07-06 Fujirebio Inc Chemiluminescent assay for peroxidase activity
JPH02291299A (en) 1989-02-14 1990-12-03 Takeda Chem Ind Ltd Method for enhancing chemiluminescence
US5106732A (en) 1989-02-14 1992-04-21 Takeda Chemical Industries, Ltd. Method for enhancement of chemiluminescence
JPH0335147A (en) 1989-07-03 1991-02-15 Doujin Kagaku Kenkyusho:Kk Detection of chemiluminescence
JPH07327694A (en) 1994-06-14 1995-12-19 Hitachi Chem Co Ltd Reagent for chemoluminescence measurement and measuring method therefor
JPH08313443A (en) 1995-05-19 1996-11-29 Kdk Corp Modified chemiluminescence measuring method
US6565894B1 (en) * 1999-11-05 2003-05-20 Francis X. Smith Healthcare formulations comprising imidazole and hydrogen peroxide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Hadd et al. "Stopped-Flow Kinetics Investigation of the Imidazole-Catalyzed Peroxyoxalate Chemiluminescenece Reaction" J. Org. Chem. 1998, vol. 63, pp. 3023-3031. *

Also Published As

Publication number Publication date
US20080027222A1 (en) 2008-01-31

Similar Documents

Publication Publication Date Title
KR101396691B1 (en) Use of ammonium and phosphate ions for improving the detection of luciferase
US20070190589A1 (en) Enzymatic fluorometric assay for cAMP and adenylate cyclase
CN105181970A (en) Stable kit for detecting homocysteine
FI69641B (en) OVER REAGENTS FOR THE CONSTRUCTION OF CREATIVES
JPH09511581A (en) Chemical assay calibration method
CN106868096B (en) High-stability and low-cost glucose detection reagent by hexokinase method
US20130203068A1 (en) Dual-acceptor time-resolved-fret
KR20250028294A (en) Phasing and prephasing correction of base calling in next-generation sequencing
US7977493B2 (en) Chemiluminescent reagents
US7718389B2 (en) Stabilizing composition and stabilizing method of coelenterazine solution for high-throughput measurement of luciferase activity
JP4591820B2 (en) Chemiluminescent reagent
CN101514984B (en) Reagent for determining serum free carnitine
CN108884030B (en) Improved labeling of nucleophiles using bipyridines
US10799603B2 (en) Kinase and/or phosphatase sensing via hydroxyquinoline-sensitized chelates
SU1041568A1 (en) Reagent for detecting adenosine-5-triphosphate
US5972635A (en) Sulfonic acid group buffered dry analytical element for quantitative analysis of creatine kinase or its MB isozyme
RU2164241C2 (en) Reagent for adenosine 5'-triphosphate assay
JP3992467B2 (en) Method for simultaneous preparation of sample capable of measuring cAMP and cGMP with high sensitivity
JP2000166550A (en) Stabilization of bioluminescent reagent
Hammler Synthesis and Characterization of Dye-Labeled Nucleotides to Follow Protein Activity
Davidsen Tools to investigate aspartate limited proliferation of cancer cells
US8871520B2 (en) Uracil-specific fluorescence detection reaction and method for examining dihydropyrimidine dehydrogenase deficiency
SU1495382A1 (en) Method of determining the quantity of high-molecular alcohols in solution
WO2021241446A1 (en) Method for detecting target molecule in specimen, and target molecule detection kit
Lindbrg et al. Bioluminescent determination of ATP in ischemic rat heart

Legal Events

Date Code Title Description
AS Assignment

Owner name: CHEMCO SCIENTIFIC CO., LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NOZAKI, OSAMU;MUNESUE, MOTONORI;KAWAMOTO, HIROKO;REEL/FRAME:018259/0004

Effective date: 20060721

AS Assignment

Owner name: NOZAKI, OSAMU, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CHEMCO SCIENTIFIC CO., LTD.;REEL/FRAME:019803/0254

Effective date: 20070901

Owner name: MUNESUE, MOTONORI, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CHEMCO SCIENTIFIC CO., LTD.;REEL/FRAME:019803/0254

Effective date: 20070901

Owner name: CHEMCO SCIENTIFIC CO., LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CHEMCO SCIENTIFIC CO., LTD.;REEL/FRAME:019803/0254

Effective date: 20070901

Owner name: KAWAMOTO, HIROKO, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CHEMCO SCIENTIFIC CO., LTD.;REEL/FRAME:019803/0254

Effective date: 20070901

STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20190712